Memory effects of prior subculture may impact the quality of multiomic perturbation profiles.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
16 Jul 2024
Historique:
medline: 8 7 2024
pubmed: 8 7 2024
entrez: 8 7 2024
Statut: ppublish

Résumé

Mass spectrometry-based omics technologies are increasingly used in perturbation studies to map drug effects to biological pathways by identifying significant molecular events. Significance is influenced by fold change and variation of each molecular parameter, but also by multiple testing corrections. While the fold change is largely determined by the biological system, the variation is determined by experimental workflows. Here, it is shown that memory effects of prior subculture can influence the variation of perturbation profiles using the two colon carcinoma cell lines SW480 and HCT116. These memory effects are largely driven by differences in growth states that persist into the perturbation experiment. In SW480 cells, memory effects combined with moderate treatment effects amplify the variation in multiple omics levels, including eicosadomics, proteomics, and phosphoproteomics. With stronger treatment effects, the memory effect was less pronounced, as demonstrated in HCT116 cells. Subculture homogeneity was controlled by real-time monitoring of cell growth. Controlled homogeneous subculture resulted in a perturbation network of 321 causal conjectures based on combined proteomic and phosphoproteomic data, compared to only 58 causal conjectures without controlling subculture homogeneity in SW480 cells. Some cellular responses and regulatory events were identified that extend the mode of action of arsenic trioxide (ATO) only when accounting for these memory effects. Controlled prior subculture led to the finding of a synergistic combination treatment of ATO with the thioredoxin reductase 1 inhibitor auranofin, which may prove useful in the management of NRF2-mediated resistance mechanisms.

Identifiants

pubmed: 38976734
doi: 10.1073/pnas.2313851121
doi:

Substances chimiques

Arsenic Trioxide S7V92P67HO
Auranofin 3H04W2810V

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2313851121

Déclaration de conflit d'intérêts

Competing interests statement:P.P. is the founder and CEO of PHIO scientific GmbH. All other authors declare no competing financial interests.

Auteurs

Patricia Bortel (P)

Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.
Vienna Doctoral School in Chemistry, University of Vienna, Vienna 1090, Austria.

Gerhard Hagn (G)

Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.
Vienna Doctoral School in Chemistry, University of Vienna, Vienna 1090, Austria.

Lukas Skos (L)

Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.
Vienna Doctoral School in Chemistry, University of Vienna, Vienna 1090, Austria.

Andrea Bileck (A)

Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.
Joint Metabolome Facility, University of Vienna and Medical University of Vienna, Vienna 1090, Austria.

Verena Paulitschke (V)

Department of Dermatology, Medical University of Vienna, Vienna 1090, Austria.

Philipp Paulitschke (P)

PHIO scientific GmbH, Munich 81371, Germany.
Faculty of Physics, Ludwig-Maximilians University of Munich, Munich 80539, Germany.

Lion Gleiter (L)

PHIO scientific GmbH, Munich 81371, Germany.

Thomas Mohr (T)

Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.
Center of Cancer Research, Department of Medicine I, Medical University of Vienna and Comprehensive Cancer Center, Vienna 1090, Austria.

Christopher Gerner (C)

Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.
Joint Metabolome Facility, University of Vienna and Medical University of Vienna, Vienna 1090, Austria.

Samuel M Meier-Menches (SM)

Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.
Joint Metabolome Facility, University of Vienna and Medical University of Vienna, Vienna 1090, Austria.
Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH